AUTHORS
Guo Qiu, ningxin zhang2, Qifa Liu, MD3, Xi Xu4
AFFILIATIONS
1 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
2 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
3 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
4 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
ABSTRACT
Background: Acute myeloid leukemia (AML) comprises heterogeneous leukemic cell states. Leukemic stem/progenitor cells (LSPCs) mediate persistence and relapse, but their heterogeneity and the contribution of differentiated AML cells to LSPC maintenance remain unclear. We investigated how AML cell-state composition and interactions among leukemic subpopulations influence treatment response, relapse and survival.
Methods: We integrated single-cell RNA sequencing, single-cell chromatin accessibility sequencing, spatial single-nucleus RNA sequencing and targeted DNA sequencing across 524 bone marrow samples from 305 newly diagnosed and 8 relapsed AML patients. In total, 1,304,913 AML cells were analyzed to define subpopulations, differentiation states, transcriptional programs, spatial organization and clinical associations. Non-negative matrix factorization identified leukemic programs, and a secretory-support index (SSI) was derived from ligand–receptor interactions and transcriptional features of mature AML cells and LSPCs. The SSI was validated in TCGA and BEAT AML cohorts. Functional relationships were examined using primary AML differentiation, co-culture and chemoresistance assays, neutralizing antibodies, murine leukemia models, gene-deficient models, serial and limiting-dilution transplantation, and human AML xenografts.
Results: Integrated single-cell analysis resolved 30 stable AML subpopulations along a continuous hierarchy from LSPC-like to mature myeloid states. Several LSPC populations were associated with favorable outcome, whereas the C4 LSPC population and multiple mature AML populations were associated with shorter survival and increased relapse, demonstrating functional heterogeneity within the LSPC compartment.
Six transcriptional programs were identified. NMF5 showed the poorest outcome, increased at relapse and retained adverse prognostic associations in TCGA and BEAT. NMF5 contained poor-outcome LSPCs together with mature AML cells enriched for cytokine secretion, chemotaxis and paracrine signaling. Mature NMF5 AML cells expressed WNT10B, TGFB1, CCL3 and other secreted factors, whereas NMF5 LSPCs showed increased WNT/β-catenin, TGF-β, survival and microenvironment-response programs. Ligand–receptor analysis identified signaling between these compartments, including WNT10B–FZD/LRP5 and TGFB1–TGFBR interactions.
The SSI stratified overall survival in the discovery cohort and both external cohorts. Mature AML cells from SSI-high patients expressed higher WNT10B, TGFB1 and CCL3. SSI-high LSPCs generated partially differentiated progeny that retained increased paracrine factor expression. SSI-high mature AML cells enhanced LSPC chemoresistance and transferred resistance to SSI-low LSPCs, indicating that differentiated progeny support LSPC survival.
Spatial single-nucleus RNA sequencing of 43 treatment-naïve specimens identified eight spatial districts. One district containing LSPCs and paracrine AML cells was associated with higher measurable residual disease and shorter event-free and overall survival. Paracrine AML cells were closer to LSPCs, and WNT and TGF-β pathway activity in LSPCs decreased with increasing distance.
Neutralization of WNT10B or TGF-β1 reduced paracrine-mediated chemoresistance. Wnt10b loss decreased β-catenin activity, colony formation, functional LSPC frequency, drug resistance and leukemia burden, while prolonging survival in MLL-AF9 and Hoxa9-Meis1 models. Tgfb1 loss similarly impaired LSPC function and leukemia progression. TGF-β1 targeting also reduced leukemia burden and enhanced chemotherapy response in human AML xenografts.
Conclusions: Poor-outcome AML contains a mature paracrine compartment generated from LSPCs that sustains LSPC function through WNT10B and TGF-β1. This leukemia-derived supportive niche promotes chemoresistance, relapse and adverse outcome and identifies WNT10B and TGF-β1 signaling as actionable dependencies.
DISCLOSURES
Guo Qiu: No relevant conflicts of interest to declare.